Compare PMTS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | TSHA |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 1.5B |
| IPO Year | 2015 | 2020 |
| Metric | PMTS | TSHA |
|---|---|---|
| Price | $13.86 | $5.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.00 | $10.56 |
| AVG Volume (30 Days) | 51.7K | ★ 3.4M |
| Earning Date | 11-04-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $515,576,000.00 | $6,310,000.00 |
| Revenue This Year | $13.70 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $11.71 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $11.64 | $1.05 |
| 52 Week High | $34.25 | $6.02 |
| Indicator | PMTS | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 49.30 |
| Support Level | $14.60 | $5.58 |
| Resistance Level | $14.83 | $6.02 |
| Average True Range (ATR) | 0.66 | 0.31 |
| MACD | -0.29 | -0.11 |
| Stochastic Oscillator | 2.23 | 36.07 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.